This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Background: Rhegmatogenous retinal detachment (RRD) repair by pars plana vitrectomy (PPV) combined air tamponade has many advantages compared with PPV combined gas tamponade. However, there are controversial outcomes in RRD cases involving the lower quadrants. Objective: This study aimed to evaluate the efficacy and safety of PPV combined air tamponade in patients with RRD compared with PPV combined gas tamponade and whether it could be a safe alternative to PPV combined gas tamponade. Methods: The PubMed, Embase, and Cochrane Library databases published until September 2022 were comprehensively searched for studies that compared PPV combined with air tamponade and gas tamponade in patients with RRD. The rate of primary treatment success, best-corrected visual acuity (BCVA), and postoperative complications were extracted from the final eligible studies. The mean difference (MD) and risk ratio (RR) were calculated for continuous and dichotomous variables, respectively, with 95% confidence intervals (CIs). Results: A total of 8 studies with 668 eyes in the air tamponade group and 944 in the gas tamponade group were included. There was no significant difference in the rate of primary treatment success between the air tamponade group and the gas tamponade group (RR = 1.00, P = 0.79). In addition, the subgroup analysis suggested that whether retinal breaks were located above or below, there was no significant difference in either rate of primary treatment success (RR = 0.99, P = 0.89; RR = 1.02, P = 0.45). There was no significant difference in mean BCVA 3 months after surgery (MD = -0.02, P = 0.50). For postoperative complications, mean postoperative IOP was lower in the air tamponade at one day (MD = -4.24, P < 0.001), and there was no significant difference between the two groups at 7 days (MD = -0.45, P = 0.71), one month (MD = -0.69, P = 0.33), and 3 months (MD = 0.69, P = 0.35) after surgery. The rate of epiretinal membrane (ERM) development was lower in the air tamponade group (RR = 0.48, P = 0.04). Conclusions: For patients with uncomplicated RRD, PPV combined air tamponade is a feasible and safe alternative to PPV combined gas tamponade, regardless of the position of retinal breaks, with a similar primary treatment success rate, postoperative BCVA, and fewer postoperative complications.
Esophageal cancer (EC) is one of the most common digestive system malignancies in the world. The combined modality treatment of EC is usually surgery and radiation therapy, however, its clinical efficacy for advanced patients is relatively limited. Ferroptosis, a new type of iron-dependent programmed cell death, is different from apoptosis, necrosis and autophagy. In recent years, many studies have further enlightened that ferroptosis plays an essential role in the occurrence, development and metastasis of tumors. Targeting ferroptosis stimulates a new direction for further exploration of oncologic treatment regimens. Furthermore, ferroptosis has a critical role in the immune microenvironment of tumors. This paper reviews the mechanism of ferroptosis and the ferroptosis research progress in the treatment of EC. We further elaborate the interaction between ferroptosis and immunotherapy, and the related mechanisms of ferroptosis participation in the immunotherapy of EC, so as to provide new directions and ideas for the treatment of EC.
Background: Vascular invasion is closely related to the prognosis of hepatocellular carcinoma (HCC). Increasing evidence suggests that miRNAs can serve as biomarks to predict prognosis in various tumors. Thus, the aim of this study was to develop a novel, vascular invasion-related miRNA signature for prediction of HCC prognosis.Methods: Differentially expressed miRNAs (DEMs) between HCC samples with vascular invasion and without vascular invasion were obtained from GSE67140. MiRNAs expression profiles and clinical information for 344 patients were collected from The Cancer Genome Atlas database, and the patients were randomized (1:1) to training set and validation set. LASSO regression model was employed to identify survival-associated DEMs and establish risk score in the training set. Moreover, risk score was verified in the validation set. And nomogram based on risk score and clinical information was constructed to improve the prediction of prognosis. Meanwhile, four online tools were used to predict target genes and enrichment analysis was utilized to explore the biological pathway of the miRNAs.Results: A novel three-miRNA signature was screened including hsa-mir-210, hsa-mir-149 and hsa-mir-99a, and risk score was established for HCC prognosis prediction. Patients were divided into the low-risk group and high-risk group according to risk score. High-risk group both have higher hazard of death compared with low-risk group in training set and validation set. And the 5-year AUC of risk score were 0.718, 0.674 and 0.697 in training set, validation set and the total set, respectively. The C-index of nomogram was 0.724, and calibration curves showed nomogram had high concordance to predict 1- ,3- , and 5-year survival rates among HCC patients. Furthermore, enrichment analysis identified several tumor-associated pathways including Ras signaling pathway, PI3K-Akt signaling pathway, and MAPK signaling pathway and so on, which may contribute to explain the potential molecular mechanisms of above miRNAs.Conclusion: This study developed a risk assessment model based on three miRNAs, which could accurately predict the prognosis of HCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.